Senescent cells stop dividing, but remain active. Some persist and contribute to tissue damage.
We’re investigating whether a combination of signals on their surface could identify them and guide their selective removal.
THE PRECISION LENS
SENESCENT CELLConceptual visualization, not experimental results.
Explore with the slider or buttons. The image does not represent an available therapy.
Between both perspectives
Recognize before acting.
The first challenge is finding a pattern that distinguishes the cells we aim to remove.
The selectivity, safety and efficacy of this approach have yet to be demonstrated experimentally.
OUR AMBITION
Many moreyears of life.
With vitality. With independence. With life ahead.
Our long-term ambition is to significantly extend human life and the years we live in good health. We are investigating a more selective intervention targeting cells that contribute to age-related decline.
If our hypothesis is validated and can be developed into a safe, effective intervention, it could contribute to that future.
Milestone-led investment
From hypothesis to evidence.
We’re seeking investors who share a far-reaching ambition. The next funding will turn our analysis and study design into an initial independent experiment, with a clear decision at the end of each stage.
Our own analysis of published data has shaped a proposed approach to selective cell recognition.
Two patent applications.
Filed in Spain. The protection strategy is underway; the applications have not yet been granted.
An experimental route.
A staged research plan and an external analytical quotation provide the basis for arranging execution.
INVESTMENT ROADMAP
Every milestone, a step forward.
NOW · INITIAL FUNDING
€50k
Initial funding target
First evidence.
Test the proposed signals in primary human cells, compare them with controls and guide the next confirmatory step.
DECISION MILESTONEInterpretable data to decide how to proceed.
NEXT · EXTEND THE EVIDENCE
€200k
Indicative cumulative funding horizon. Includes the initial €50k.
Experimental robustness.
If the results support progression, extend the evaluation to independent donors and additional controls to test reproducibility.
DECISION MILESTONEEvidence to select what merits further development.
FURTHER AHEAD · DEVELOPMENT
To be defined
Funding shaped by the findings
Functional selectivity.
Develop a recognition mechanism and test whether it can act on the cells of interest while sparing control cells.
DECISION MILESTONEFunctional data to decide whether to proceed.
Indicative fundraising targets, not fixed quotations. The €200k includes the initial stage and expanded experimental validation. Functional selectivity development and later stages require separate funding. Each stage depends on results, the agreed scope and execution arrangements.
PUBLIC INVESTOR OVERVIEWThe project in perspective.
Vision and execution
An original vision. A defined strategy. Acacia Labs brings together its own analysis, intellectual property and experimental planning in a roadmap designed to turn the hypothesis into evidence.
How it will be executed
Research outsourced to specialist laboratories. Contracts, cell supply and scientific leadership will be arranged before work begins.
What the capital enables
Biological material, sample preparation and analysis, scientific oversight and documentation of results. Spending is planned by milestone.
What it will help decide
Whether the evidence supports expanding the study, adjusting the approach or stopping a line of investigation. The initial stage evaluates cellular signals; testing selective elimination requires later development.
An initial conversation can explore the scope, intended use of funds and decision milestones. Reserved technical documentation is shared under appropriate confidentiality arrangements.
